-

Shareholder Alert: Robbins LLP Reminds Investors Covetrus, Inc. (CVET) Sued for Making Misleading Statements

SAN DIEGO & PORTLAND, Maine--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Covetrus, Inc. (NASDAQ: CVET) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between February 8, 2019 and August 12, 2019. Covetrus operates as an animal-health technology and services company.

If you suffered a loss as a result of Covetrus' misconduct, click here.

Covetrus, Inc. (CVET) Accused of Misleading Shareholders

According to the complaint, on April 23, 2018, Henry Schein announced the spin-off and merger of the Animal Health Business of Henry Schein with Vets First Choice ("VFC"). Covetrus shares began trading on February 8, 2019. Throughout the class period and in the Offering Documents for the spin-merger, Henry Schein highlighted Covetrus' strengths and touted Covetrus as a technology-enabled animal health business with a comprehensive service and technology platform and supply chain infrastructure. These benefits were reaffirmed later in Covetrus' financial reports and the Company reassured that the integration was "on track" to hit financial targets. However, in reality, Covetrus' strengths were overstated and the costs of the integration as well as the separation of Covetrus from Henry Schein had been much higher than represented. Then, on August 13, 2019, Covetrus shockingly reported a net loss of $0.09 per share rather than the expected increase of $0.17 per share and slashed its EBITDA guidance from estimates of $250 million to a realized $200 million. In its explanation, Covetrus confessed the undisclosed difficulties it was having in platform integration and separations costs from Henry Schein. Since this news, Covetrus' stock has plummeted with a decline of $9.71, or 42%, per share and currently trades at around $13.50.

Covetrus, Inc. (CVET) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click Here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:CVET

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Reminds Primo Brands Corporation Stockholders on the January 12, 2026 Lead Plaintiff Deadline – Contact us today for information about the PRMB class action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Primo Brands Corporation (NYSE: PRMB) purports to be a leading North American branded beverage company focused on healthy hydration, offering responsibly sourced products across multiple formats, channels, and price points, and for a wide range of consumer occasions. Its products are distributed in every U.S. state and in Canada. Who is part of the class? The case purportedly represents stockholders who purchased or otherwise acquired (i) the co...

Robbins LLP Reminds Telix Pharmaceuticals Ltd. Stockholders About the January 9, 2026 Lead Plaintiff Deadline – Contact Us Today for Information About the TLX Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. What is the class period? February 21, 2025 - August 28, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or acquired Telix securities during the class peri...

Robbins LLP Reminds Freeport-McMoran Inc. Stockholders of the January 12, 2026 Lead Plaintiff Deadline – Contact us today for information about the FCX class action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Freeport-McMoran Inc. (NYSE: FCX) is a mining company. What is the class period? February 15, 2022 - September 24, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Freeport during the class period because the Company allegedly misled investors regarding safety at its mines. For more information, submit a form, email attorney Aaron Dumas, Jr....
Back to Newsroom